Video

Dr. Garcia-Manero on Rigosertib in Patients with High-Risk MDS After Failure of Hypomethylating Agents

Guillermo Garcia-Manero, MD, chief, Section of Myelodysplastic Syndromes, deputy chair, Translational Research, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the multikinase inhibitor rigosertib in patients with MDS who have failed hypomethylating agents.

Guillermo Garcia-Manero, MD, chief, Section of Myelodysplastic Syndromes, deputy chair, Translational Research, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the multikinase inhibitor rigosertib in patients with myelodysplastic syndromes (MDS) who have failed hypomethylating agents.

Garcia-Manero says this agent isn’t a specific selective kinase inhibitor. This is important because the data that has started to emerge for studies of hypomethlating failure biology implicates kinase deregulation in this context. Garcia-Manero says it makes sense that an inhibitor of kinase may have a role in this space.

Data has been published that has found that at the time of failure, a subset of patient acquire mutations from FLT3 and RAS and other data has found that MAP-kinase pathway is activated in these patients, Garcia-Manero says.

Garcia-Manero says a clinical trial is being prepared that will consist of biomarkers looking at the patients that are responding, or not responding, to rigosertib and will help researchers better understand kinase deregulation in this group of patients.

<<<

View more from the 2015 MDS Symposium

Related Videos
FRCSI, FRCSEd, medical director, Thoracic Cancer Program, and associate executive director, AdventHealth Cancer Institute
Benjamin P. Levy, MD, clinical director, Medical Oncology, Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital; and associate professor, oncology, Johns Hopkins University School of Medicine
Russell Hales, MD, director, Thoracic Oncology Multidisciplinary Program, associate professor, clinical radiation oncology and molecular radiation sciences, and director, thoracic multidisciplinary clinic, John Hopkins University School of Medicine
Estelamari Rodriguez, MD, MPH, associate director, Community Outreach – Thoracic Oncology, Sylvester Comprehensive Cancer Center
Kathleen N. Moore, MD, MS
Dana M. Chase, MD
Misty D. Shields, MD, PhD, assistant professor, clinical medicine, Department of Medicine, Division of Hematology/Oncology, Indiana University (IU) School of Medicine; and associate member, Experimental and Developmental Therapeutics, IU Melvin and Bren Simon Comprehensive Cancer Center
Corey J. Langer, MD, director, Thoracic Oncology, Penn Medicine; and professor, medicine (hematology-oncology), the Hospital of the University of Pennsylvania, Perelman School of Medicine
R. Wendel Naumann, MD, professor and director of gynecologic oncology research, and associate medical director of clinical trials, Levine Cancer Institute, Atrium Health
Stéphanie Lheureux, MD, PhD, clinician investigator, Cancer Clinical Research Unit, Princess Margaret Cancer Centre